Q-omics provides the consensus-scored SYT14 profile across patient tissues and cancer cell-line models. SYT14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SYT14 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SYT14 RNA expression shows 17,262 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, HNSC, and PCPG as cancer lineages where SYT14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT14 survival associations across molecular data types. SYT14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT14 RNA expression–survival associations across cancer types. High SYT14 expression shows unfavorable associations in KIRC, HNSC, MESO and LIHC, but favorable associations in ACC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SYT14 RNA expression.
This table summarizes SYT14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SYT14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT14 shows lower tumor expression in KIRC and higher tumor expression in HNSC, KIRP, LUSC, LUAD and BRCA. The HNSC box plot shows higher SYT14 RNA expression in tumor versus normal tissue (log2 FC = +0.406, t-test p < 0.001).
This table shows molecular features associated with SYT14 in patient tissues and cancer cell lines. In patient samples, SYT14 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
